(Press-News.org) PITTSBURGH, Feb. 13, 2014 – University of Pittsburgh Cancer Institute (UPCI) scientists have shown that old drugs might be able to do new tricks.
By screening a library of FDA-approved anticancer drugs that previously wouldn't have been considered as a treatment for a rare type of cancer, UPCI scientists were surprised when they found several potential possibilities to try if the cancer becomes resistant to standard drug treatment.
The discovery, which will be published in the February 15th issue of Cancer Research, demonstrates that high-throughput screening of already FDA-approved drugs can identify new therapies that could be rapidly moved to the clinic.
"This is known as 'drug repurposing,' and it is an increasingly promising way to speed up the development of treatments for cancers that do not respond well to standard therapies," said senior author Anette Duensing, M.D., assistant professor of pathology at UPCI. "Drug repurposing builds upon previous research and development efforts, and detailed information about the drug formulation and safety is usually available, meaning that it can be ready for clinical trials much faster than a brand-new drug."
Dr. Duensing and her team ran the screening on 89 drugs previously approved by the FDA in an attempt to find more treatment options for patients with gastrointestinal stromal tumors (GISTs), which are uncommon tumors that begin in the walls of the gastrointestinal tract. According to the American Cancer Society, about 5,000 cases of GISTs occur each year in the United States with an estimated five-year survival rate of 45 percent in patients with advanced disease.
GISTs are caused by a single gene mutation and can be successfully treated with the targeted therapy drug imatinib, known by the trade name Gleevec. However, about half of the patients treated with Gleevec become resistant to the drug within the first two years of treatment.
After studying how samples of GIST responded to various concentrations of the 89 drugs in the laboratory, Dr. Duensing and her colleagues identified 37 compounds that showed some anticancer activity in at least one of the concentrations tested. Importantly, they noted that the most promising candidates all belonged to only two major drug classes: inhibitors of gene transcription and so-called topoisomerase II inhibitors. Based on these findings, the research team selected the two most promising compounds for further testing – gene transcription inhibitor mithramycin A, which is in clinical trials to treat Ewing sarcoma, and topoisomerase II inhibitor mitoxantrone, which is used in metastatic breast cancer and leukemia.
Both drugs were highly effective in fighting GIST in laboratory tests. Moreover, the mechanism of action of each drug was linked to the specific underlying biology of these tumors.
"These are very encouraging results," said Dr. Duensing. "The next step will be moving our findings to clinical exploration to see if the results we found in the lab hold up in patients."
INFORMATION:
Additional co-authors of this study include Sergei Boichuk, M.D., Ph.D., Derek J. Lee, B.S., Keith R. Mehalek, M.S., Kathleen R. Makielski, M.S., Danushka S. Seneviratne, B.S., Rolando Cuevas, M.S., Joshua A. Parry, B.S., Matthew F. Brown, Ph.D., James P. Zewe, B.S., and Shih-Fan Kuan, M.D., Ph.D., all of Pitt; Agnieszka Wozniak, Ph.D., Patrick Schöffski, M.D., M.P.H., and Maria Debiec-Rychter, M.D., Ph.D., all of the Catholic University in Leuven, Belgium; Nina Korzeniewski, Ph.D., of the University of Heidelberg in Germany; and Takahiro Taguchi, M.D., of Kochi Medical School in Japan.
This research was supported by American Cancer Society grant no. RSG-08-092-01-CCG, The Life Raft Group, GIST Cancer Research Fund and the Howard Hughes Medical Institute.
About UPCI
As the only NCI-designated comprehensive cancer center in western Pennsylvania, UPCI is a recognized leader in providing innovative cancer prevention, detection, diagnosis, and treatment; bio-medical research; compassionate patient care and support; and community-based outreach services. UPCI, a partner with UPMC CancerCenter, investigators are world-renowned for their work in clinical and basic cancer research.
http://www.upmc.com/media
Contact: Allison Hydzik
Phone: 412-647-9975
E-mail: HydzikAM@upmc.edu
Contact: Jennifer Yates
Phone: 412-647-9966
E-mail: YatesJC@upmc.edu END
Laboratory detective work points to potential therapy for rare, drug-resistant cancer
2014-02-13
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Researchers find source of new lineage of immune cells
2014-02-12
The elusive progenitor cells that give rise to innate lymphoid cells—a recently discovered group of infection-fighting white blood cells—have been identified in fetal liver and adult bone marrow of mice, researchers from the University of Chicago report early online in the journal Nature.
Innate lymphoid cells (ILCs) are among the first components of the immune system to confront certain pathogens. They have a critical function at mucosal barriers—locations such as the bowel or the lung—where the body comes in direct contact with the environment. Yet they went undetected ...
NREL report finds similar value in 2 CSP technologies
2014-02-12
Parabolic troughs and dry-cooled towers deliver similar value for concentrating solar power (CSP) plants, despite different solar profiles, a new report by the Energy Department's National Renewable Energy Laboratory has found.
The report, "Estimating the Performance and Economic Value of Multiple Concentrating Solar Power Technologies in a Production Cost Model," found that the value of delivered energy of dry-cooled tower and parabolic trough CSP plants, integrated with thermal energy storage, are quite similar.
CSP with thermal energy storage is a unique source of ...
Double mastectomy halves death risk for women with BRCA-related breast cancer
2014-02-12
TORONTO, ON, February 11, 2014 — Women with BRCA-related breast cancer who have a double mastectomy are nearly 50 per cent less likely to die of breast cancer within 20 years of diagnosis compared to women who have a single mastectomy, according to a new study led by Women's College Hospital's Kelly Metcalfe.
The findings, published in the British Medical Journal, suggest a double mastectomy may be an effective first-line treatment for women with early-stage breast cancer who carry a BRCA1 or BRCA2 genetic mutation. The BRCA1/2 genes belong to a class of genes that ...
Skin reactions during radiation therapy preventable
2014-02-12
Severe skin reactions during radiation therapy could be prevented by applying a thin transparent silicone dressing to the skin from the first day of treatment, clinical research from New Zealand shows.
Although many skincare products have been tested in clinical trials over the years, until now none have been able to completely prevent severe skin reactions, says senior lecturer Dr Patries Herst of University of Otago Wellington's Department of Radiation Therapy.
Dr Herst and her team of radiation therapists, oncology nurses and medical physicists have completed five ...
The genome of clonal raider ant provides a promising model to study social evolution and behavior
2014-02-12
Social insects, which usually have specialized behavioral groups (also called castes), are important models for social evolution and behavior researches. How division of labor in insect societies is regulated is an outstanding question and not fully understood yet. However, in many social insect species, experimental control over important factors that regulate division of labor, such as genotype and age, is limited. In a study published online on February 6th in Current Biology, researchers from Rockefeller University and BGI-Shenzhen have sequenced the genome of the queenless ...
Common infections linked to stroke in children; vaccines may reduce risk
2014-02-12
Common infections are associated with a significantly higher chance of stroke in children, but routine vaccinations may help decrease risk, according to preliminary research (abstract 39) presented at the American Stroke Association's International Stroke Conference 2014.
"The protective association of routine vaccination against childhood stroke provides a widely available means of prevention, and this information can easily be dispersed by pediatric healthcare providers," said Nancy Hills, Ph.D., M.B.A., lead researcher and assistant professor of neurology at the University ...
More awareness, fast response key to combatting stroke in children
2014-02-12
Parents and healthcare professionals must be aware that children can have strokes and be prepared to respond to symptoms, according to research presented at the American Stroke Association's International Stroke Conference 2014.
As in adults, warning signs of stroke in children are: sudden weakness or numbness of the face, arm or leg; sudden difficulty in speaking; sudden problems in seeing; sudden difficulty walking; dizziness; or sudden onset of headache.
Researchers interviewed 28 parents whose child had a stroke about factors that contributed to delayed arrival to ...
Cocaine may increase stroke risk within 24 hours of use
2014-02-12
Cocaine greatly increases ischemic stroke risk in young adults within 24 hours of use, according to research presented at the American Stroke Association's International Stroke Conference 2014.
Ischemic strokes occur when a blood vessel supplying blood to the brain becomes blocked, preventing a continuous supply of blood to the brain.
"We set out to understand what factors contribute to stroke risk in young adults," said Yu-Ching Cheng, Ph.D., research scientist at Baltimore Veterans Affairs Medical Center and assistant professor of medicine at the University of Maryland ...
Weather changes may be linked with stroke hospitalization, death
2014-02-12
Stroke hospitalization and death rates may rise and fall with changes in environmental temperature and dew point, according to research presented at the American Stroke Association's International Stroke Conference 2014.
"Weather is not something people would typically associate with stroke risk; however, we've found weather conditions are among the multiple factors that are associated with stroke hospitalizations," said Judith H. Lichtman, Ph.D., M.P.H., study author and an associate professor in Epidemiology at the Yale School of Public Health in New Haven, Conn.
Researchers ...
Lost and found: New beetle collected by Darwin 180 years ago published on his birthday
2014-02-12
In 1832 Charles Darwin disembarked from HMS Beagle in Bahia Blanca, Argentina where he travelled by land to Buenos Aires. In Bahia Blanca, Darwin collected several fossils of large mammals along with many other living organisms, including several insects. More than 180 years later on Darwin's birthday, February 12, scientists name after him a long lost but new to science beetle genus and species from this collection.
The beetle was discovered and described by Dr. Stylianos Chatzimanolis, an entomologist at the University of Tennessee at Chattanooga, USA as a new genus ...